RECURRENT WHO GRADE III GLIOMA
Clinical trials for RECURRENT WHO GRADE III GLIOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT WHO GRADE III GLIOMA trials appear
Sign up with your email to follow new studies for RECURRENT WHO GRADE III GLIOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Engineered immune cells take aim at Hard-to-Treat brain tumors
Disease control OngoingThis early-stage trial tests a new type of CAR T-cell therapy designed to target a protein called MMP2 found on glioblastoma cells. The treatment uses a scorpion toxin fragment (chlorotoxin) to help the immune cells find and attack the tumor. Nineteen patients with recurrent or p…
Matched conditions: RECURRENT WHO GRADE III GLIOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jul 02, 2026 03:00 UTC
-
Stem cells could help chemo target brain tumors
Disease control OngoingThis early-phase trial tests a new approach for people with aggressive brain tumors that have come back. Doctors place genetically modified neural stem cells directly into the tumor to make it more sensitive to the chemotherapy drug irinotecan. The study involves 18 participants …
Matched conditions: RECURRENT WHO GRADE III GLIOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New hope for young brain tumor patients: drug combo targets IDH mutations
Disease control OngoingThis early-phase study tests a new drug (BGB-290) combined with chemotherapy (temozolomide) in teens and young adults with a type of brain tumor called glioma that has an IDH mutation. The goal is to find the safest dose and see how well the combination works for both newly diagn…
Matched conditions: RECURRENT WHO GRADE III GLIOMA
Phase: PHASE1 • Sponsor: University of California, San Francisco • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
Engineered immune cells take on Hard-to-Treat brain cancers
Disease control OngoingThis early-stage trial tests a personalized immunotherapy for people with malignant glioma that has returned or not responded to standard treatment. The patient's own T-cells are collected, genetically modified in a lab to recognize and attack glioma cells, and then infused back …
Matched conditions: RECURRENT WHO GRADE III GLIOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 26, 2026 13:08 UTC